- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03647605
Pilot Study: VR Mind and VR Mind+ Intervention
Pilot Study: Feasibility, Usability and Safety Assessment of VR Mind and VR Mind+ Intervention
The aim of the pilot study is feasibility, usability and safety assessment of VR Mind intervention. In particular the subject of assessment will be:
- the length of the laboratory session utilizing virtual reality exposure (feasibility),
- the ergonomics and ease of use for both patients and system operators (usability),
- the frequency of side effect occurrence as a result of virtual reality exposure (ie. Vertigo) (safety).
The results pilot study will be used in the designing a clinical trial aimed for testing efficacy and safety of VR Mind intervention.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Mazowieckie
-
Warszawa, Mazowieckie, Poland, 02-957
- Instytut Psychiatrii i Neurologii
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18-50 y.o.
- Confirmed DSM-IV-TR criteria for Social Anxiety Disorder (SAD).
- Signing informed consent
Exclusion Criteria:
- Occurrence of SAD symptoms inconsistent with DSM-IV-TR criteria and with psychiatric interview (SCID-I; Structured Clinical Interview)
Occurrence and/or recognition:
- psychosis,
- bipolar disorder,
- mental retardation
Exclusion based on interview:
- pregnancy,
- drug addiction,
- alcohol addiction,
- participating in the experimental session while intoxicated
- (current) neurological treatment of chronic disease of central nervous system,
- epilepsy,
- paroxysmal vertigo,
- presence of suicidal thoughts , tendencies or attempts,
- participant is taking drugs from benzodiazepine group, other sedatives, narcotic drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VR Mind
Two VR Mind sessions using experimental virtual reality scenarios.
During these two sessions, participants will be exposed to virtual reality environment, for 2 x 10 min each session.
|
Two VR Mind sessions using virtual reality scenarios concerning social situations in which social phobics are prone to experience anxiety.
The pilot study will consist of two scenarios: "Public Speaking in Lecture Hall" and "Telephoning in Public".
Two sessions are planned, each containing two expositions to virtual reality environment, each lasting 10 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility_1: Number of participants, who have completed 4 laboratory sessions within 2 weeks.
Time Frame: At the end of 4th laboratory session within 2 weeks
|
Number of participants, who have completed 4 laboratory sessions within 2 weeks.
|
At the end of 4th laboratory session within 2 weeks
|
Feasibility_2: Number of virtual reality exposure sessions completed in predefined time.
Time Frame: At the end of 2nd and 3th laboratory session within 2 weeks
|
Number of virtual reality exposure sessions completed in predefined time.
|
At the end of 2nd and 3th laboratory session within 2 weeks
|
Usability_ 3: immersion, perceived reality and engagement
Time Frame: At the end of 2 and 3 laboratory session within 2 weeks
|
3 items with 7-point scale, where 1 is "Totally agree" and 7 "Totally disagree":
|
At the end of 2 and 3 laboratory session within 2 weeks
|
Safety_1: occurrence and severity of simulator sickness
Time Frame: During 2nd and 3th laboratory session within 2 weeks
|
Simulator sickness is expected adverse effect of the VR. Hence, the Simulator Sickness Questionnaire (SSQ; Kennedy, Lane, Berbaum, Lilienthal, 1993) will be administered as a primary outcome measure to evaluate safety of the VR intervention. Total SSQ score equal to or higher than 10 will be used as a preliminary cut-off for simulator sickness (Balk et al., 2013). Individual scores will be corrected for baseline (pre-VR) symptom severity. Only items with a pre-VR - post-VR increase will contribute to a final SSQ score. All post-intervention SSQ scores >10 will be analyzed further for its association with study drop-outs and other intervention required. The adverse effect will be classified as:
|
During 2nd and 3th laboratory session within 2 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Global Impression
Time Frame: During 1st and 4th session within 2 weeks
|
Clinical Global Impression (Guy, 1976) - is a single item, 7 point scale used by clinicians to asses the severity of illness, where 1 is labeled as "Normal, not at all ill" and 7 is labeled as "Among the most extremely ill patients".
|
During 1st and 4th session within 2 weeks
|
Patient Global Impression
Time Frame: During 1st and 4th session within 2 weeks
|
Patient Global Impression - is a single item, 4 point scale used by patients to asses their impression of severity of their illness and quality of their functioning in everyday life, where 1 is labeled as "Normal" and 4 is labeled as "Severe".
|
During 1st and 4th session within 2 weeks
|
Liebowitz Social Anxiety Scale
Time Frame: During 1st and 4th session within 2 weeks
|
Liebowitz Social Anxiety Scale (LSAS; Leibowitz, 1987) The scale is composed of 24 items, depicting various social situations. For each item, participants assess their fear (from 1 - "No fear" to 4 - "Severe") and avoidance (from 1 - "Never" to 4 - "Usually"). LSAS has 3 scores, summing the results for particular items - fear (0-72), avoidance (0-72) and total score (0-144). |
During 1st and 4th session within 2 weeks
|
Beck Depression Inventory
Time Frame: During 1st and 4th session within 2 weeks
|
During 1st and 4th session within 2 weeks
|
|
Subjective Units of Distress
Time Frame: During 2nd and 3th session within 2 weeks
|
Subjective Units of Distress (SUD) SUD is a subjective measure of perceived fear in certain situation. The scale range is from 0 ("Totally relaxed) to 100 ("Highest distress/fear/anxiety/discomfort that you have ever felt"). |
During 2nd and 3th session within 2 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Paweł Mierzejewski, prof, Tomorrow Sp. z o.o.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- POIR.01.01.01-00-0636/16-00
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Social Phobia
-
San Diego State UniversityNational Institute of Mental Health (NIMH)CompletedSocial Anxiety Disorder | Social PhobiaUnited States
-
Umeå UniversityUppsala UniversityCompleted
-
Umeå UniversityCompleted
-
Stanford UniversityNational Institute of Mental Health (NIMH)CompletedSocial PhobiaUnited States
-
University of MinnesotaAstraZenecaCompletedSocial PhobiaUnited States
-
Modum BadCompleted
-
VU University of AmsterdamCompletedSocial Anxiety Disorder | Social PhobiaNetherlands
-
Pherin Pharmaceuticals, Inc.CompletedSocial Anxiety Disorder | Social PhobiaUnited States
-
McMaster UniversityHamilton Health Sciences Corporation; Janssen-Ortho Inc., CanadaTerminated
Clinical Trials on VR Mind
-
Tomorrow Sp. z o.o.National Center for Research and Development, PolandCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingVirtual Reality | Post Operative Pain | Coronary Artery Bypass Grafting | Heart Surgery | Post Operative AnxietyNetherlands
-
University of HoustonCompleted
-
Mental Health Services in the Capital Region, DenmarkTrygFonden, Denmark; The Danish Mental Health Foundation; Defactum, Central Denmark...CompletedProblem Behavior | Anxiety Disorders | Anxiety | Depressive Symptoms | Conduct Disorder | Oppositional Defiant Disorder | Depressive Disorders | Other Behavioral and Emotional Disorders With Onset Usually Occurring in Childhood and AdolescenceDenmark
-
University of Colorado, BoulderCompletedEating Disorders in AdolescenceUnited States
-
Hong Kong Metropolitan UniversityCompletedEffect of Mediterranean-DASH Intervention for Neurodegenerative Delay Plus Forest Bathing (MINDdiet)High Blood PressureHong Kong
-
University of UlsterCompletedCognitive ChangeUnited Kingdom
-
Johns Hopkins UniversityCenters for Medicare and Medicaid Services; Jewish Community Services; Johns...CompletedComprehensive Home-based Dementia Care Coordination for Medicare-Medicaid Dual Eligibles in MarylandDementia | Caregiver BurdenUnited States
-
Mental Health Services in the Capital Region, DenmarkTrygFonden, Denmark; The Danish Mental Health FoundationCompletedDepressive Disorder | Problem Behavior | Anxiety Disorders | Anxiety | Depressive Symptoms | Conduct Disorder | Oppositional Defiant Disorder | Behavior Disorders
-
National Institute of General Medical Sciences...Completed